Skip to main content
Veterinary Medicines

EURICAN DAP LYOPHILISATE AND SOLVENT FOR SUSPENSION FOR INJECTION

Not authorised
  • Canine adenovirus 2, strain DK13, Live
  • Canine distemper virus, strain BA5, Live
  • Canine parvovirus, strain CAG2, Live

Product identification

Medicine name:
EURICAN DAP LYOPHILISATE AND SOLVENT FOR SUSPENSION FOR INJECTION
Eurican DAP
Active substance:
  • Canine adenovirus 2, strain DK13, Live
  • Canine distemper virus, strain BA5, Live
  • Canine parvovirus, strain CAG2, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine adenovirus 2, strain DK13, Live
    2.50
    log10 50% cell culture infectious dose
    /
    1.00
    Dose
  • Canine distemper virus, strain BA5, Live
    4.00
    log10 50% cell culture infectious dose
    /
    1.00
    Dose
  • Canine parvovirus, strain CAG2, Live
    4.90
    log10 50% cell culture infectious dose
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AD02
Authorisation status:
  • Surrendered
Authorised in:
  • Hungary
Package description:
  • Plastic box of 10 vials of lyophilisate (1 dose)
  • Plastic box of 50 vials of lyophilisate (1 dose)
  • Plastic box of 10 vials of solvent (1 ml)
  • Plastic box of 50 vials of solvent (1 ml)
  • Plastic box of 10 vials of lyophilisate (1 dose) and 10 vials of solvent (1 ml)
  • Plastic box of 50 vials of lyophilisate (1 dose) and 50 vials of solvent (1 ml)

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Boehringer Ingelheim Animal Health France
Marketing authorisation date:
Manufacturing sites for batch release:
  • Boehringer Ingelheim Animal Health France
Responsible authority:
  • Directorate Of Veterinary Medicinal Products
Authorisation number:
  • 3722/X/16 NÉBIH ÁTI
Date of authorisation status change:
Reference member state:
  • France
Procedure number:
  • FR/V/0305/001